Brian McKelligon - Dec 6, 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
President/CEO
Signature
/s/ Brian McKelligon
Stock symbol
AKYA
Transactions as of
Dec 6, 2022
Transactions value $
-$58,900
Form type
4
Date filed
12/8/2022, 03:01 PM
Previous filing
Sep 9, 2022
Next filing
Feb 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Options Exercise $1.52K +5K +6.25% $0.30* 85K Dec 6, 2022 Direct
transaction AKYA Common Stock Sale -$60.4K -5K -5.88% $12.08 80K Dec 6, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Options Exercise $0 -5K -1.46% $0.00 338K Dec 6, 2022 Common Stock 5K $0.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated May 16, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.955 to $12.53, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F3 The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, subject to reporting person's continuous employment.